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INTRODUCTION
The past two decades have heralded dramatic 
improvements in outcomes for people living 
with heart failure with reduced ejection 
fraction (HFrEF).1 The more widespread 
implementation of disease modifying phar-
macological therapies,2 supported by land-
mark trials of renin- angiotensin system 
inhibitors3 and beta- blockers4 have improved 
longevity despite a background of an ageing 
and increasingly multimorbid population. 
Although the benefits of comprehensive 
pharmacological therapies are clear, the 
real- world attainment of target doses5 6 and 
utilisation of novel agents such as angio-
tensin receptor- neprilysin inhibitors (ARNI)7 
remain low. Furthermore, HFrEF remains a 
disease associated with significant morbidity 
and reduced survival relative to those without 
HFrEF, even after taking into account comor-
bidities.8 Recently, trials have demonstrated 
improved outcomes in people with HFrEF 
receiving sodium- glucose co- transporter 
2 inhibitors (SGLT2i).9 10 However, it is 
currently unclear how these agents will be 
used alongside established therapies. Now 
is therefore an opportune moment to pause 
and reflect on our current practice, barriers 
to further progress and how future guide-
lines might work better for our patients. In 
this viewpoint we summarise how our current 
linear approach, on a background of increas-
ingly complex pharmacotherapy has the 
potential to cause confusion and consequent 
delays which could lead to even worse attain-
ment of optimal therapies. On the other 
hand, a more parallel approach to the initi-
ation and optimisation of the Four Pillars of 
Heart Failure would simplify our approach, 
yielding benefits for our patients and health-
care systems.
HOW DID WE GET HERE?
Heart failure guidelines are based around 
inhibition of the renin- angiotensin and 
sympathetic nervous systems, two funda-
mental pathways which drive the pathophys-
iology of HFrEF using ACE inhibitors (ACEi) 
and beta- blockers. In both European2 and 
American guidelines11 additional therapies 
are recommended for patients who ‘remain 
symptomatic’ with persistently impaired left 
ventricular (LV) function despite maximally 
tolerated doses of ACEi and beta- blockers. 
These guidelines differ subtly regarding the 
timing of mineralocorticoid receptor antag-
onists (MRA) relative to other therapies but 
are otherwise broadly similar, advocating 
a linear approach. This attempts to avoid 
‘unnecessary’ treatments in patients who 
‘respond’ but has several important limita-
tions. First, while guidelines do not stipulate 
a time interval between alterations to therapy, 
the need for further assessment and re- eval-
uation of LV function inevitably results in 
delays initiating additional agents as well as 
contributing further follow- up and imaging 
costs. In clinical practice it typically takes 
many months before patients receive opti-
mised doses of these medications, and many 
never do, even where integrated hospital 
and community care is available.5 Second, 
the barrier of ‘response’ is confusing and 
misplaced: does ‘response’ mean asympto-
matic or merely improved? In our experi-
ence, while patients often feel better, they 
rarely become asymptomatic (NYHA (New 
York Heart Association) class 1),12 an obser-
vation supported by real- world data even 
in those receiving ARNI.13 14 Moreover, we 
should consider whether a highly subjec-
tive and poorly reproducible assessment is 
appropriate to determine our allocation 
of life- saving treatments.15 Hence, criteria 
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requiring repeat assessment act as a barrier to initiating 
additional therapies such as MRA or ARNI,7 which are 
regarded as ‘second- line’ due to the hierarchical frame-
work which places greater emphasis on therapies based 
on the chronological sequence in which the trials were 
performed. There is no logical basis to assume that drug 
classes trialled earliest would be the most beneficial, yet 
this is what guidelines imply. Therefore, if we are to make 
progress, future guidelines must address these limitations 
and incorporate the Four Pillars of Heart Failure into a 
comprehensive disease modifying programme for all 
people living with HFrEF.
LEARNING LESSONS FROM ARNI
The PARADIGM- HF trial showed that a combination 
of angiotensin receptor blocker and a neprilysin inhib-
itor (sacubitril- valsartan) was superior to an ACEi in 
preventing cardiovascular deaths or hospitalisation 
for heart failure (HR 080, 95% CI 0.73 to 0.87) and 
reducing all- cause mortality (HR 0.84, 95% CI 0.76 to 
0.93).16 Despite overwhelming efficacy which led to the 
trial being stopped early, the utilisation of ARNI in the 
real- world has been suboptimal, with less than 1% pene-
tration in eligible patients. The reluctance of physicians 
to prescribe ARNI may in part be that, unusually, the 
recommendations are based on a single trial, studied 
in an ‘A+B vs C’ fashion. Furthermore, the comparator 
was a submaximal dose of enalapril compounded by 
lower blood pressure in those allocated ARNI suggesting 
undertreatment in the control arm.16 It has also been 
suggested that the trial was additionally biased in favour 
of the novel agent due to a double drug run- in period of 
unequal times, in which those randomised to ARNI had 
already received an ACEi and were therefore pre- selected 
(20% of patients were lost during the run- in period).17 
Drug doses are related to outcomes in HFrEF18–20 and 
the HR for the composite outcome in PARADIGM- HF 
between sacubitril- valsartan and enalapril was similar to 
the comparison of high and low dosing of lisinopril in 
the ATLAS trial.21 However, post- hoc analysis has shown 
that the point estimates for the benefit of low dose ARNI 
compared with low dose ACEi were identical to the point 
estimate of the overall trial,22 and real- world data have 
shown clear improvements in outcomes, symptoms and 
quality of life compared with standard of care ACEi.23
Another difficulty employing ARNI across the board 
includes the wash- out period required following cessation 
of ACEi due to risks of angioedema. Although not insur-
mountable, such requirements challenge heart failure 
programmes facing reduced face- to- face appointments 
due to service redesign and the current pandemic. Hence, 
if the benefits of the activity are perceived (whether 
correctly or incorrectly) to be minimal, physician inertia 
may prevail. To counter this, initiating ARNI at the point 
of diagnosis would mitigate the risk of inertia while also 
providing a more effective treatment to patients during 
the period of highest risk.
IMPLEMENTING NOVEL AGENTS INTO HEART FAILURE 
PATHWAYS
The efficacy of SGLT2i in addition to standard therapies 
for people with HFrEF has been confirmed with consistent 
and near identical 25% risk reduction of the primary end 
point of cardiovascular death or hospitalisation for heart 
failure from both dapagliflozin and empagliflozin.10 24 
Both trials also demonstrated a slow of decline in renal 
function; EMPEROR- Reduced showed a 50% relative risk 
reduction for the composite renal endpoint10 (although 
this was non- significant in DAPA- HF).24
It is anticipated that more than four out of five people 
with HFrEF in contemporary registries25 will be eligible 
based on the inclusion criteria of these trials. The bene-
ficial effects on renal outcomes are particularly attractive 
in a disease process typically associated with progressive 
decline of kidney function which often prevents the initi-
ation or intensification of renin- angiotensin system inhib-
itors. Furthermore, SGLT2i are safe, with a low incidence 
of serious side effects (no patients without diabetes devel-
oped ketoacidosis in DAPA- HF or EMPEROR- Reduced), 
a lack of dosing considerations and minimal effects on 
blood pressure.
Given the somewhat simpler approach taken in trials of 
SGLT2i, the ease of use and clear benefits, it is likely that 
uptake among physicians will be enthusiastic, although 
it is yet unclear how these agents might fit into our 
current practice. There is a risk that SGLT2i become an 
additional agent for patients who do not ‘respond’ with 
conventional pharmacological therapy, rather than a 
fundamental Pillar of Heart Failure. The totality of the 
available evidence suggests the benefits of SGLT2i are 
consistent across subgroups, including diabetes status, 
baseline ARNI and symptoms. SGLT2i must therefore 
be regarded as a unique class of medication with a novel 
mechanism of action to be used in all eligible patients.
THE POSSIBILITIES OF A COMPREHENSIVE APPROACH
The four drug classes are complementary to each other 
and cross- trial comparisons have shown that a compre-
hensive disease modification strategy beyond the treat-
ments which most patients receive (ACEi and beta- 
blocker) with ARNI, MRA and SGLT2i are associated with 
improved outcomes. A typical patient aged 65 years can 
expect to live an additional 5 years if receiving a compre-
hensive strategy with the Four Pillars, compared with 
conventional therapy.26
INERTIA: KNOW YOUR ENEMY
Drugs, trial design and side effects aside, the key obstacle 
to therapy intensification is physician inertia in patients 
who are deemed to have stabilised or ‘responded’ to 
treatment. For some with a recent decompensation this 
might be appropriate,27 28 but the relevant clinical trials 
were carried out in ambulatory patients receiving stable 
doses of previous generations of medical therapy, most 
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of which had class II symptoms.10 16 24 Of particular rele-
vance to SGLT2i, a striking result from DAPA- HF was the 
early benefit from dapagliflozin, with a reduction in wors-
ening heart failure events observed within 28 days.24
SIMPLIFY TO PROGRESS
We propose a novel conceptual framework for the imple-
mentation of pharmacological therapies in HFrEF, in 
which the Four Pillars of Heart Failure are introduced 
in parallel, very early in the patient pathway with subse-
quent optimisation of dosing where required (figure 1).24 
The rate of dose increments can be tailored to the patient 
and the service. For most patients, low dose ARNI and 
SGLT2i could be started simultaneously, followed within 
a few days by low dose beta- blocker and MRA, followed 
by up- titration. While others have suggested that initia-
tion with beta- blocker alongside SGLT2i might be more 
optimal,29 we believe that the exact sequent of initiation 
is unimportant, as long as all Four Pillars are introduced 
within the first few weeks of diagnosis—although with the 
lack of dosing considerations and clear evidence from 
randomised trials of an early beneficial effect,27 SGLT2i 
are an obvious first choice.
This approach is at odds with current practice and a 
fundamental shift away from the linear approach advo-
cated by guidelines, including the recent technology 
appraisal of dapagliflozin from the UK.30 Nevertheless, it 
remains the case, that very few patients become asymp-
tomatic with even optimal doses of disease- modifying 
therapy suggesting that slow up- titration, followed by a 
decision to embark on the next step based on symptoms 
is folly.
It seems likely that impairment of renal function 
following up- titration of ARNI and MRA will become 
lesser concerns following the introduction of SGLT2i 
into care pathways, however, real- world data are vital to 
confirm the safety and feasibility of this approach. Those 
caring for people with heart failure must be cognisant 
that early increases in creatinine with SGLT2i are tran-
sient and be reassured that in the long- term the less rapid 
decline in renal function in patients receiving SGLT2i will 
allow more complete renin- angiotensin system blockade.
CONCLUSION
The introduction of SGLT2i to the treatment of HFrEF 
is a chance for us to revisit whether current guidelines 
for the treatment of HFrEF are fit for purpose. Many 
patients have waited for weeks or months before ever 
seeing a cardiologist and receiving a diagnosis, and 
further delays to treatments have the potential to cause 
great harm. Moving forwards, we must recognise heart 
failure for what it is, an incurable disease with a mortality 
rate similar to many forms of cancer, where any delays 
cost lives. Once we have done so we need to implement 
pathways that offer rapid initiation and, where required, 
up- titration of life- extending therapies.
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